Navigation Links
Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year
Date:5/12/2008

ts regarding: (i) our net sales and net income expectations for the fiscal year ending March 31, 2009; (ii) our expectation of improving operating margins; (iii) our expectation of improving our gross margins in the future; (iv) our expectations that initial international sales to Canada will begin in fiscal 2009; (v) our expectations regarding product liability defense costs; (vi) our expectations regarding new products. These forward-looking statements are based on the Company's current expectations and are subject to a number of risks and uncertainties, many of which cannot be predicted or quantified and are beyond the Company's control. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. Factors that could cause actual results to differ materially from the Company's expectations include: (a) the severity and timing of the cold season; (b) the possibility that future sales of our products will not be as strong as expected; (c) the possibility that supply issues may impact future sales of our products; (d) the possibility that our products may face increased competition or negative publicity; (e) the potential impact of current and future product liability litigation; (f) regulatory issues or public relations challenges; (g) the possibility of delays or other difficulties in selling our products in Canada or in implementing new product improvements and introducing to the marketplace new products and brands; (h) and the possibility that expenses, including legal expenses, product reserves, and expenses associated with adverse litigation outcomes, may exceed budgeted amounts. Other factors that could cause actual results to differ materially from the Company's expectations are described in the Company's Transition Report on Form 10-KT filed on May 30, 2007, under the heading "Risk Factors," filed pursuant to the Securities Exchange Act of 1934. We do not undertake, and we sp
'/>"/>
SOURCE Matrixx Initiatives, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Matrixx Initiatives, Inc. Sets Time for Discussion of Fiscal 2008 Financial Results
2. Rising Medical Solutions Partners With myMatrixx to Deliver Integrated Pharmacy Management Solutions
3. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference
4. Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share
5. Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2008 Financial Results
6. Matrixx Initiatives, Inc. Updates 2007/2008 Cold Season Trends and Fiscal 2008 Sales and Earnings Outlook
7. Matrixx Initiatives, Inc. to Present at the William Blair & Company Small-Cap Growth Stock Conference
8. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
9. New Medicare and Medicaid Data Released: Featuring Up-To-Date Enrollment Trends, State Initiatives, Regional Market Share and Prescription Drug Benefits
10. CryoCath Announces Fiscal 2008 Second Quarter Results
11. OmniSonics Medical Technologies Announces First Patient Enrolled in SONIC II REGISTRY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...ough the number of jobs created in the medical fie...ed a different kind of slowdown: they laid off few... Seattle, WA (PRWEB) July 25, 2...dical field slowed in June overall, pharmaceutical...hat will be music to the ears of sales representat...
(Date:7/25/2008)...f Marketing Exclusivity Begins -, CORONA, Calif.,...uticals, Inc. (NYSE: WPI ), a leading specialty p...bsidiary has commenced commercial,shipment of its ... the 40mg,strength from its Davie, Florida manufac...atson has 180 days of marketing exclusivity for be...
(Date:7/25/2008)...5 /PRNewswire/ -- Sagent Pharmaceuticals, Inc.,a ...oday announced that it,has launched amiodarone HCl...ted for the treatment and prophylaxis of frequentl...ically unstable ventricular,tachycardia -- a poten...nt,s amiodarone HCl injection will be available im...
(Date:7/25/2008)...5 /PRNewswire/ -- AutoGenomics, Inc. today,announc...orm S-1 with the,Securities and Exchange Commissio... of shares of its common stock. The number of shar... expected to be offered by,AutoGenomics, Inc., and...en,determined., J.P. Morgan Securities Inc. is ac...
Breaking Medicine News(10 mins):Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2
...vouch for the difficulty of capturing a clear pict...es, however, sometimes the motion is exactly what ...d the pathological protein mis-folding and assembl... a host of human disorders, including diabetes and...
...merican research, there is still hope for the couc...urch, director of the Laboratory of Preventive Med...ch Center at Louisiana State University, shows tha...d daily exercise dose, a substantial and immediate...
... the outrage over an insensitive caption for the p...lia, comes the news that a pre-schooler was found...al for unwanted babies. The drop-off was opened b...e southern city of Kumamoto to discourage abortion...
...g Administration (FDA) today approved Evicel Fibri...cally helps control oozing from small blood vesse...n effective means to stop oozing from small vessel...ring, compression or other standard techniques are...
Other Medicine News:Health News:Decoding Protein Structures Helps Illuminate Cause of Diabetes 2Health News:Spare Just Ten Minutes A Day For A Healthier Heart 2Health News:Three-year-old Abandoned in Box Meant for Unwanted Babies in Japan 2
(Date:7/23/2008)...uly 23 /- FluoroPharma Inc., a compan... for the Positron Emission Tomography,(PET) market...s novel,Fluorine-18 labeled tracer for myocardial ...cardiovascular product to complete Phase I clinica...igned to assess the blood flow in the,heart (myoca...
(Date:7/23/2008)...July 23 /- Dendreon Corpora...cts the Independent Data,Monitoring Committee (IDM...of overall survival relating to the Company,s Phas...oma Treatment, also known as D9902B) clinical tria...ompany,s investigational,active cellular immunothe...
(Date:7/22/2008)...efficacy results from a multi-center 293-patient E...ronto Stock Exchange Symbol: CYT, MONTREAL, July ...es,Inc., the global leader in cryotherapy products...t results previously presented from three,European...rctic Front(R),were published earlier today in th...
(Date:7/22/2008)...eting to Discuss Development Plan Completed Succes...tCall/ -- Amarin Corporation,plc (NASDAQ: AMRN ) ...,officials at the U.S. Food and Drug Administratio...AMR101 for the treatment of,hypertriglyceridemia. ...ding to Phase 3 with AMR101 in hypertriglyceridemi...
Breaking Medicine Technology:FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 3Polished to perfection 23702 1Polished to perfection 23702 2Zooming in on genetic shuffling 3984 1Zooming in on genetic shuffling 3984 2RNA emerges from DNAs shadow 3982 1RNA emerges from DNAs shadow 3982 2RNA emerges from DNAs shadow 3982 3James Briscoe awarded 2008 EMBO Gold Medal 3980 1James Briscoe awarded 2008 EMBO Gold Medal 3980 2James Briscoe awarded 2008 EMBO Gold Medal 3980 3
...nce of Recurrent Wheeze by,Almost Half, ABBOTT PAR...wswire-FirstCall/ -- Abbott and MedImmune today an...uly issue of Journal of,Pediatrics, showing that t...recurrent wheezing in premature infants by almost,...ure infants without,chronic lung disease who recei...
...Myeloma Workshop held in,Kos, Greece demonstrates ...h bortezomib, dexamethasone and lenalidomide plus,...y multiple,myeloma, and as a single agent in patie...obulinemia, NEW YORK, June 29, 2007 /PRNewswire-Fi...nnounced that 4 posters were,presented at the 11th...
Other Medicine Technology:New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 2New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 3New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 4New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 5Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 2Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 3Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 4Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 5Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 6Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 7
...te Focus from Thermo Labsystems was designed speci...performance. Advanced features such as the new fa...n microvolumes help to define this as a new leader...le handle plate offers a custom fit for different ...
...igital offers improved ergonomics for today's exac...fied grippy finger rest and the large display wind...ipette Digitals also feature soft-touch tip ejecti....) and super blow-out for 0.2 - 50ul micro volume ...
...els cover the range from 2ul to 5000ul. Fills and...prevents inadvertent volume change. Novel hand gr...te is autoclavable at 121C(250F). To prevent corr...ble for one-handed operation. Auto or Normal trig...
...pettor is the #1 Pipettor for sub-microliter pipet...iability. Continuously adjustable. Features lPLUS,...ter. Easy interchangeable ejector buttons to fit l...ip ejector with three different lengths. Air-displ...
Medicine Products: